Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers
- PMID: 29285512
- PMCID: PMC5733322
- DOI: 10.21037/atm.2017.09.02
Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers
Abstract
The current standard of adjuvant therapies for patients with early stage non-small-cell lung cancers largely depends on the stage of disease. Liquid biopsy for circulating tumor DNA (ctDNA) has the potential to detect minimal residual disease, depict genomic evolution, guide precision medicine to individual patients and revolutionize the management of early stage lung cancers. In light of the seminal work published by Abbosh and colleagues, we discuss the potential paradigm changing clinical implications of ctDNA, the biological and technological challenges to consider, and the future of ctDNA driven therapeutic studies.
Keywords: Liquid biopsy; circulating tumor DNA (ctDNA); genetic sequencing; lung cancer.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Figures

Comment on
-
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Nature. 2017. PMID: 28445469 Free PMC article.
References
-
- Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 2017;35:2960-74. 10.1200/JCO.2017.72.4401 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources